search
Back to results

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Primary Purpose

Gastrointestinal Disease, Esophageal Cancer, Lung Cancer

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Breathing Test
Respiratory Symptoms Questionnaire
Pet Scan
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Gastrointestinal Disease focused on measuring Cancer of esophagus, Gastrointestine, esophagus cancer, Positron emission tomography, PET scan, Nitric oxide, NO, NO Breathing Test, Respiratory symptoms questionnaire

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with pathologic diagnosis of esophagus cancer.
  2. For the cohort 2, patients with the pathological diagnosis of lung cancer.
  3. For the cohort 3, patients with any pathological diagnosis of a thoracic malignancy.
  4. Patients must sign informed consent.
  5. Patients who will receive concurrent chemotherapy and radiation therapy will be undergoing PET-scan for restaging between 25 and 75 days after radio therapy.
  6. For Lung Cohort, patients who will receive concurrent chemotherapy and radiation therapy or greater or equal to 3 weeks of radiation therapy alone.
  7. For the Lung Cohort, participation in a PET-scan for restaging between 40-50 days after radiotherapy is required. 10 patients will receive a second PET-scan within 2-7 days as a test for reproducibility.

Exclusion Criteria:

  1. Significant pleural effusion as evaluated by the attending Radiation Oncologist is excluded.
  2. Patients who received thoracic radiotherapy prior to the study.

Sites / Locations

  • UT MD Anderson Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1: Esophagus Cancer

Cohort 2: Lung Cancer

Arm Description

Breathing Test + Respiratory Symptoms Questionnaire

Breathing Test + Respiratory Symptoms Questionnaire

Outcomes

Primary Outcome Measures

Comparison Patient's PMRR + Mean Exhaled NO Measurement
Association between exhaled nitric oxide (NO) and PMRR (pulmonary metabolic radiation response). FDG-PET imaging (to determine PMRR) and exhaled NO assessed three times on same day of PET imaging.

Secondary Outcome Measures

Full Information

First Posted
March 20, 2009
Last Updated
August 27, 2014
Sponsor
M.D. Anderson Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00867477
Brief Title
PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide
Official Title
A Biomarker Study Comparing the Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide in Patients Who Receive Thoracic Radiotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical research study is to use a new breathing test that measures the amount of nitric oxide (NO) you exhale. Researchers want to compare your "NO" levels to the amount of inflammation in your lungs, as measured using a positron emission tomography (PET) scan reading, and with respiratory symptoms questionnaire.
Detailed Description
Lung Cancer Cohort: NO Breathing Test: If you agree to take part in this study, you will have a breathing test performed before starting radiation therapy, weekly during radiation therapy and, about 6 weeks after the end of radiation therapy on the same day of your restaging PET scan. The breathing test measures how much NO you exhale while breathing. To complete this test, you will exhale into a device called an "NO breath analyzer" for 10 seconds. You will repeat this test 3 times. The results of this test will give researchers information about possible inflammation in your lungs. The results of this test will be compared to the results of your PET scan. For the first exhaled NO testing session, and any session in which you produce a high enough NO level, you will have the NO breath test repeated up to 4 times. The staff will ask you to exhale at different speeds during these repeated sessions, in order to learn where in your lungs the NO is coming from. Respiratory Symptoms Questionnaire: At each visit when you have NO breathing tests, you will be asked to complete a questionnaire about your breathing and any symptoms you may be having. A research assistant will be able to help you with completing the questionnaire. It should take about 10 minutes to complete the questionnaire. PET scans: After completing your radiation therapy, you will receive a PET scan as part of this study. The PET scan will be scheduled for you between 40 and 50 days after the end of the radiation therapy. A study staff member will call you with the PET scan date. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility. For up to 6 hours before the PET scan, you must not eat or drink anything except water. A small tube will be placed in your arm, and you will receive an injection of a very small amount of a mildly radioactive sugar material into your bloodstream. The radioactive nature of this injected material allows the scanner to "see" it in certain places in your body. After the injection, you will need to rest quietly until it is time for the scan. The amount of rest time may vary, but be prepared to wait for between 45 and 90 minutes. During the scan, you will lie flat on your back on a table. The scan itself may last up to 1 hour. Length of Study: You will remain on study for up to 7 months. After you have completed the breathing tests, blood draws, questionnaires, and PET scans, your participation on this study will be over. This is an investigational study. The device (called an NO breath analyzer) used in this study is FDA approved and commercially available for measuring exhaled NO levels in patients with asthma. The use of the PET scan and blood test to check lung inflammation is also investigational. Up to 150 patients (up to 47 with lung cancer) will take part in this study. All will be enrolled at MD Anderson. Esophageal Cancer Cohort: NO Breathing Test: If you agree to take part in this study, you will have a breathing test performed before starting radiation therapy, about 5 weeks later after radiation therapy is complete (at the end of radiation therapy), and the same day of your restaging PET scan. The breathing test measures how much NO you exhale while breathing. To complete this test, you will exhale into a device called an "NO breath analyzer" for 10 seconds. You will repeat this test 3 times. The results of this test will give researchers information about possible inflammation in your lungs. The results of this test will be compared to the results of your PET scan. For the first exhaled NO testing session, and any session in which you produce a high enough NO level, you will have the NO breath test repeated up to 4 times. The staff will ask you to exhale at different speeds during these repeated sessions, in order to learn where in your lungs the NO is coming from. Respiratory Symptoms Questionnaire: At each visit when you have 3 NO breathing tests, you will be asked to complete a questionnaire about your breathing and any symptoms you may be having. A research assistant will be able to help you with completing the questionnaire. It should take about 10 minutes to complete the questionnaire. Length of Study: After you have completed the breathing tests and the questionnaires, your participation on this study will be over. This is an investigational study. The device (called an NO breath analyzer) used in this study is FDA approved and commercially available for measuring exhaled NO levels in patients with asthma. Its use in patients with esophageal cancer is investigational. The optional SPECT scans using 99m Tc-HMPAO are an FDA approved standard imaging method for infection and/or inflammation. Up to 150 patients (up to 93 with esophageal cancer) will take part in this study. All will be enrolled at MD Anderson.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Disease, Esophageal Cancer, Lung Cancer
Keywords
Cancer of esophagus, Gastrointestine, esophagus cancer, Positron emission tomography, PET scan, Nitric oxide, NO, NO Breathing Test, Respiratory symptoms questionnaire

7. Study Design

Primary Purpose
Screening
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
163 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1: Esophagus Cancer
Arm Type
Experimental
Arm Description
Breathing Test + Respiratory Symptoms Questionnaire
Arm Title
Cohort 2: Lung Cancer
Arm Type
Experimental
Arm Description
Breathing Test + Respiratory Symptoms Questionnaire
Intervention Type
Procedure
Intervention Name(s)
Breathing Test
Intervention Description
Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
Intervention Type
Behavioral
Intervention Name(s)
Respiratory Symptoms Questionnaire
Other Intervention Name(s)
survey
Intervention Description
3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
Intervention Type
Procedure
Intervention Name(s)
Pet Scan
Intervention Description
Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
Primary Outcome Measure Information:
Title
Comparison Patient's PMRR + Mean Exhaled NO Measurement
Description
Association between exhaled nitric oxide (NO) and PMRR (pulmonary metabolic radiation response). FDG-PET imaging (to determine PMRR) and exhaled NO assessed three times on same day of PET imaging.
Time Frame
Before starting radiation therapy (RT), after completing RT, and approximately 5 weeks later at completion of RT, and same day of restaging PET scan.

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with pathologic diagnosis of esophagus cancer. For the cohort 2, patients with the pathological diagnosis of lung cancer. For the cohort 3, patients with any pathological diagnosis of a thoracic malignancy. Patients must sign informed consent. Patients who will receive concurrent chemotherapy and radiation therapy will be undergoing PET-scan for restaging between 25 and 75 days after radio therapy. For Lung Cohort, patients who will receive concurrent chemotherapy and radiation therapy or greater or equal to 3 weeks of radiation therapy alone. For the Lung Cohort, participation in a PET-scan for restaging between 40-50 days after radiotherapy is required. 10 patients will receive a second PET-scan within 2-7 days as a test for reproducibility. Exclusion Criteria: Significant pleural effusion as evaluated by the attending Radiation Oncologist is excluded. Patients who received thoracic radiotherapy prior to the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Guerrero, MD, PhD
Organizational Affiliation
UT MD Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
UT MD Anderson Cancer Center website

Learn more about this trial

PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

We'll reach out to this number within 24 hrs